JinwenShi
Lv3
260 积分
2023-03-16 加入
-
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
22天前
已完结
-
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
22天前
已完结
-
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
2个月前
已完结
-
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
3个月前
已完结
-
Cytokine Release Syndrome Biology and Management
5个月前
已完结
-
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study
5个月前
已完结
-
Dermatomyositis: Diagnosis and treatment
5个月前
已完结
-
Baricitinib for the treatment of cutaneous dermatomyositis: A prospective, open-label study
5个月前
已完结
-
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study
7个月前
已完结
-
Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention
8个月前
已完结